Protara Therapeutics’ (TARA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Protara Therapeutics (NASDAQ:TARA) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $23.00 price objective on the stock.

Separately, Oppenheimer lifted their price target on Protara Therapeutics from $26.00 to $30.00 and gave the stock an outperform rating in a research report on Monday, April 22nd.

Protara Therapeutics Trading Down 0.3 %

Protara Therapeutics stock opened at $2.90 on Monday. The stock has a 50-day moving average of $3.57 and a two-hundred day moving average of $2.56. Protara Therapeutics has a one year low of $1.04 and a one year high of $5.24.

Protara Therapeutics (NASDAQ:TARA) last released its earnings results on Wednesday, March 13th. The company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.13. As a group, sell-side analysts forecast that Protara Therapeutics will post -3.55 earnings per share for the current year.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.